Progress in immunotherapy for small cell lung cancer

被引：7

作者：

Zhao, Dong ^{[1
]}

Xie, Bing ^{[1
]}

Yang, Yong ^{[1
]}

Yan, Peng ^{[1
]}

Liang, Sheng-Nan ^{[1
]}

Lin, Qiang ^{[2
]}

机构：

[1] Peoples Hosp Lixin Cty, Dept Oncol, Bozhou 236700, Anhui, Peoples R China

[2] Hebei Med Univ, North China Petr Bur, Gen Hosp, Dept Oncol, 8 Huizhan Ave, Renqiu 062552, Hebei, Peoples R China

来源：

WORLD JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 11卷 / 06期

关键词：

Small-cell lung cancer; Programmed death-1 inhibitors; Cytotoxic T lymphocyte-associated antigen-4 inhibitors; Poly adenosine diphosphate ribose polymerase inhibitors; INTERLEUKIN-2; SECRETION; COMBINATION; CHEMOTHERAPY; THERAPY; DISEASE; TRIAL; PEMBROLIZUMAB; RADIOTHERAPY; IPILIMUMAB; MUTATIONS;

D O I：

10.5306/wjco.v11.i6.370

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Small-cell lung cancer (SCLC) is a special type of lung cancer that belongs to highly aggressive neuroendocrine tumors. At present, radiotherapy and chemotherapy remain the mainstay of treatment for SCLC. Progress in targeted therapies for SCLC with driver mutations has been slow, and these therapies are still under investigation in preclinical or early-phase clinical trials, and research on antiangiogenic tyrosine kinase inhibitors (e.g., anlotinib) has achieved some success. Immunotherapy is becoming an important treatment strategy for SCLC after radiotherapy and chemotherapy. In this article we review the recent advances in immunotherapy for SCLC.

引用

页码：370 / 377

页数：8

共 44 条

[1] Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer [J].

Antonia, SJ ;

Mirza, N ;

Fricke, I ;

Chiappori, A ;

Thompson, P ;

Williams, N ;

Bepler, G ;

Simon, G ;

Janssen, W ;

Lee, JH ;

Menander, K ;

Chada, S ;

Gabrilovich, DI .

CLINICAL CANCER RESEARCH, 2006, 12 (03) :878-887

[2] Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1 [J].

Byers, Lauren Averett ;

Wang, Jing ;

Nilsson, Monique B. ;

Fujimoto, Junya ;

Saintigny, Pierre ;

Yordy, John ;

Giri, Uma ;

Peyton, Michael ;

Fan, You Hong ;

Diao, Lixia ;

Masrorpour, Fatemeh ;

Shen, Li ;

Liu, Wenbin ;

Duchemann, Boris ;

Tumula, Praveen ;

Bhardwaj, Vikas ;

Welsh, James ;

Weber, Stephanie ;

Glisson, Bonnie S. ;

Kalhor, Neda ;

Wistuba, Ignacio I. ;

Girard, Luc ;

Lippman, Scott M. ;

Mills, Gordon B. ;

Coombes, Kevin R. ;

Weinstein, John N. ;

Minna, John D. ;

Heymach, John V. .

CANCER DISCOVERY, 2012, 2 (09) :798-811

[3] Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) [J].

Carvajal-Hausdorf, Daniel ;

Altan, Mehmet ;

Velcheti, Vamsidhar ;

Gettinger, Scott N. ;

Herbst, Roy S. ;

Rimm, David L. ;

Schalper, Kurt A. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

[4] INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect [J].

Chiappori, Alberto A. ;

Soliman, Hatem ;

Janssen, William E. ;

Antonia, Scott J. ;

Gabrilovich, Dmitry I. .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (06) :983-991

[5] Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies [J].

Chung, Hyun Cheol ;

Piha-Paul, Sarina A. ;

Lopez-Martin, Jose ;

Schellens, Jan H. M. ;

Kao, Steven ;

Miller, Wilson H., Jr. ;

Delord, Jean-Pierre ;

Gao, Bo ;

Planchard, David ;

Gottfried, Maya ;

Zer, Alona ;

Jalal, Shadia I. ;

Penel, Nicolas ;

Mehnert, Janice M. ;

Matos, Ignacio ;

Bennouna, Jaafar ;

Kim, Dong-Wan ;

Xu, Lei ;

Krishnan, Suba ;

Norwood, Kevin ;

Ott, Patrick A. .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) :618-627

[6] INTERLEUKIN-2 ACTIVITY IN PATIENTS WITH EXTENSIVE SMALL-CELL LUNG-CANCER - A PHASE-II TRIAL OF CANCER AND LEUKEMIA GROUP-B [J].

CLAMON, G ;

HERNDON, J ;

PERRY, MC ;

OZER, H ;

KREISMAN, H ;

MAHER, T ;

ELLERTON, J ;

GREEN, MR .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (04) :316-320

[7]

DAMICO D, 1992, ONCOGENE, V7, P339

[8] Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer [J].

Doerr, Fabian ;

George, Julie ;

Schmitt, Anna ;

Beleggia, Filippo ;

Rehkaemper, Tim ;

Hermann, Sarah ;

Walter, Vonn ;

Weber, Jean-Philip ;

Thomas, Roman K. ;

Wittersheim, Maike ;

Buettner, Reinhard ;

Persigehl, Thorsten ;

Reinhardt, H. Christian .

SCIENTIFIC REPORTS, 2017, 7

[9]

Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730

[10] Unexpected Synergy Reveals New Therapeutic Strategy in SCLC [J].

Drapkin, Benjamin J. ;

Farago, Anna F. .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2019, 40 (05) :295-297

← 1 2 3 4 5 →